ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 628,57
-0,56%
Dow Jones
39 150,33
0,04%
DAX
18 163,52
-0,41%
Brent Oil
84,39
0,00%
Bitcoin
64 411,02
0,26%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cyclacel Pharmaceuticals Inc (CYCCP)

  7. Cyclacel Pharmaceuticals Inc (CYCCP) Actualités

CYCCP

Cyclacel Pharmaceuticals (CYCCP)

Cyclacel Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CYCCP
DateHeureSourceTitreSymboleSociété
04/06/202414h00GlobeNewswire Inc.Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual MeetingNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
03/06/202414h00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
17/05/202415h56Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/05/202423h12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/05/202422h05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
13/05/202422h05Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
08/05/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
08/05/202403h56Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
08/05/202403h53Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
08/05/202403h52Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
06/05/202423h26Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
02/05/202422h30GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
30/04/202419h51AllPennyStocks.com$8 Million Private Placement Announcement Sends Biotech FlyingNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
30/04/202413h00GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
01/04/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
19/03/202421h05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
13/03/202421h05GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
07/03/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
06/03/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
20/02/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/02/202422h31Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
31/01/202422h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
30/01/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical OfficerNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
10/01/202419h35Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
26/12/202315h28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
18/12/202315h00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP DeletionsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
12/12/202322h05GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Reverse Stock SplitNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
30/11/202315h15GlobeNewswire Inc.Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SECNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CYCCP

Dernières Valeurs Consultées

ASX
SNT
Syntara
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés